High seroprevalence of hepatitis E virus (HEV) in South Transdanubia, Hungary (2010-2022).


Journal

Acta microbiologica et immunologica Hungarica
ISSN: 1588-2640
Titre abrégé: Acta Microbiol Immunol Hung
Pays: Hungary
ID NLM: 9434021

Informations de publication

Date de publication:
16 Jun 2023
Historique:
received: 10 03 2023
accepted: 19 04 2023
medline: 19 6 2023
pubmed: 9 5 2023
entrez: 9 5 2023
Statut: epublish

Résumé

Hepatitis E virus (HEV) is an increasingly recognized etiological agent of acute, chronic and extrahepatic human infections with primarily zoonotic origin in Europe. Limited numbers of comprehensive population-based studies are available related to HEV seroepidemiology, especially from Central Europe.The aim of this study was to investigate the seroprevalence and trends of total and IgM antibodies against HEV in different age groups in the population of South Transdanubia, Hungary, within a thirteen years long period between the years 2010 and 2022.We retrospectively analysed the serological test results of HEV total and HEV IgM antibodies carried out by ELISA technique using Dia.Pro (Diagnostic Bioprobes, Italy) kit from serum samples collected from patients with or without hepatitis between January 1, 2010 and December 31, 2022.The number of tested samples (∑6,996 for total antibody and ∑6,582 for IgM) increased during the study period. The average HEV total and the IgM antibody seropositivities were 33% (2,307/6,996 samples) and 9.6% (642/6,582 samples), respectively, in the study population. The HEV total antibody seropositivity varied in different age groups between 3.9% (age group 1-5 years) and 58.6% (86-90 years) and showed an increasing positivity by age. At the age groups >50 years, nearly half (43%) of the population had antibodies against HEV. The HEV IgM positivity had an increasing trend of up to 13.9% in the age group 81-85 years.High HEV total and IgM antibody seroprevalence were detected in South Transdanubia, Hungary, confirming that this region is highly endemic for HEV infections in Europe.

Identifiants

pubmed: 37159338
doi: 10.1556/030.2023.02010
doi:

Substances chimiques

Immunoglobulin G 0
Hepatitis Antibodies 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-125

Auteurs

Benigna Balázs (B)

Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Pécs, Hungary.

Ákos Boros (Á)

Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Pécs, Hungary.

Péter Pankovics (P)

Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Pécs, Hungary.

Gábor Reuter (G)

Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Pécs, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH